RxDoctor Payments Data

Frank Ditz, MD

Family Medicine · Melbourne, FLNPI 1184704124

Payments from drug & device makers

$40,816in general payments, 2019–2025

Across 576 payments — averaging $70.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Idorsia Pharmaceuticals US Inc$31K
  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • AbbVie$965
  • Amarin Pharma, Inc.$669
  • plus $5K from 33 others

What the payments were for

  • Speaking & faculty fees$27,05266%
  • Travel & lodging$2,2165%
  • Food & beverage$11,54228%
  • Education$50%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,816 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$297,927
Medicare patients
384
Services billed
2,939

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$100,311
EliquisApixaban73$82,475
OtezlaApremilast12$58,974
TrulicityDulaglutide35$38,819
RybelsusSemaglutide20$33,474
JardianceEmpagliflozin24$26,185
XareltoRivaroxaban25$20,529
FarxigaDapagliflozin Propanediol12$17,625
MyrbetriqMirabegron12$13,392
Breo ElliptaFluticasone/Vilanterol26$12,893
Aimovig AutoinjectorErenumab-Aooe12$8,586
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen211$5,717
PremarinEstrogens, Conjugated17$5,040
Atorvastatin Calcium359$2,853
Levothyroxine Sodium190$2,733

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,531$133,785102 claims
PfizerEliquis, Premarin$627$87,51590 claims
AmgenOtezla$269$58,97412 claims
Lilly USA, LLCTrulicity$1,084$38,81935 claims
Boehringer IngelheimJardiance$161$26,18524 claims
Johnson & JohnsonXarelto$116$20,52925 claims
AstraZenecaFarxiga$1,372$17,62512 claims
Astellas Pharma US IncMyrbetriq$46$13,39212 claims
GSKBreo Ellipta$555$12,89326 claims
AbbVieArmour Thyroid$965$1,95121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →